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Summary. Prolonged erections (pharmacologically in-
duced erections over 6 hours) are the most inconvenient 
side effects encountered in the diagnosis and therapy of 
erectile dysfunction with intracavernous injection of 
vasoactive drugs. Out of a total of 29 prolonged erec- 
tions, 26 were seen after diagnostic use in 300 patients 
and 3 after therapeutic application in more than 4800 
protocolled autoinjection of a standardized vasoactive 
solution (papaverine hydrochloride 15 mg/ml and phen- 
tolamine mesylate 0.5 mg/ml). In 25 of these 29 prolong- 
ed erections intracavernous injections of the alpha-recep- 
tor stimulant metaraminol was done and led to flaccidity 
in all cases. Another patient with a papaverine-induced 
erection lasting 26 h did not respond to intracavernous 
metaraminol and required puncture and aspiration; he 
lost spontaneous erectability and cavernosal response to 
vasoactive drugs. Metaraminol was also injected in- 
tracavernosally in a further 32 patients with phar- 
macologically induced full erections: flaccidity was ob- 
tained in all patients. 
Since intracavernous injection of vasoactive substances 
has proven easy to manage, safe and effective in the diag- 
nosis and therapy of erectile dysfunction, it has found 
widespread use in patients with erectile failure [1, 2, 
9-13]. However, as an untoward side effect, prolonged 
erection (pharmacologically induced erection lasting over 
6 h) has been observed with increasing frequency [2, 3, 
9-13]. At first Brindley reported prolonged erections in 
16 patients responding to intracavernous administration 
of phenoxybenzamine, which ceased spontaneously after 
22 h [2]. Later he mentioned another patients with pro- 
longed erections lasting up to 40 h. Every patient was 
treated successfully with intracavernous injection of the 
alpha-receptor stimulant metaraminol [3]. Zorgniotti re- 
ported a prolonged erection in 1 of 65 patients after in- 
tracavernous autoinjection of papaverine-phentolamine 
[13]. He recommended treatment with puncture and 
aspiration. We report our experience with incidence, 
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pathophysiology and treatment of prolonged erections in 
the diagnosis and treatment of erectile dysfunction with 
vasoactive drugs. The control of this serious and frequent 
side effect is an indispensable r quirement for therapy 
with intracavernous injection of vasoactive drugs. 
Patients and methods 
The intracavernous injection of the alpha-receptor stimulant meta- 
raminol was used to counteract 1 TUR- and 58 pharmacologically in- 
duced erections. The patients were divided into 6 groups as described 
below, with 10 healthy men serving as controls (Table 1). 
To prevent hematomas as a result of  puncture, aspiration or injec- 
tion, a swab was pressed for 5 min on the site where the needle had 
penetrated. Blood pressure, pulse rate and ECG were monitored closely 
over 30 min in each patient of all 6 groups. Changes in arterial inflow 
and blood gases were documented by Doppler tests and blood gas 
analyses performed on 12 patients. 
Group 1 (control group) 
Metaraminol was used in a reference group of  10 potent young men (av- 
erage age 24 years) to interrupt a complete 2-h erection induced by 
phentolamine mesylate 0.25 mg and papaverine hydrochloride 7.5 mg. 
Group 2 (prolonged erection during diagnosis) 
Between February 1985 and January 1987, 300 patients with erectile 
dysfunction underwent multidisciplinary examinations atthe BWK-hos- 
pital in Ulm to elucidate the origin of their erectile failure. Due to the 
fact that vasoactive substances were used for diagnosis, patients with 
arterio-occlusive disease (AOD), starting with stage III, cardiac dys- 
rhythmia, severe liver or kidney diseases or patients older than 65 years 
were excluded because adverse reactions were anticipated. 
Table i .  A total of 63 erections treated in 61 patients by either aspira- 
tion and puncture (4 patients of group 2) or intracavernous injection 
of  metaraminol (58 patients). Patients were assigned to 6 groups ac- 
cording to their etiology 
Group Patients Erections 
No. No. No. 
1. Control group 10 
2. Diagnostic injections 24 
3. Auto-injection therapy 3 
4. Impotent patients 20 
5. Potent patients 3 
6. TUR-P 1 
10 Full erections 
26 Prolonged erections 
3 Prolonged erections 
20 Full erections 
3 Prolonged erections 
1 Full erection 
176 
After obtaining a comprehensive history with the aid of a question- 
naire, the following tests were performed: physical examination, blood 
tests including fats, glucose tolerance and hormones (testosterone, pro- 
lactin; if applicable FSH, LH), sexual anamnesis and psychometry 
(MMPI: Minnesota Multiphasic Psychoinventory FPI: Freiburger 
Psychoinventory), bulbo-cavernosus reflex (BCR) latency and somato- 
sensory-evoked potentials (SSEP), ultrasonography of abdomen and 
large vessels, Doppler and penile-brachial index (PBI) [5]. Selective 
angiography of the pelvis and penis [4] was performed on 59 patients, 
dynamic cavernosography on 94. Subsequently, i.c. pharmaacotesting 
was done. 
After informed consent was obtained, each patient received an injec- 
tion of papaverine hydrochloride (7.5 mg) and phentolamine mesylate 
(0.25 mg) in the right proximal corpus cavernosum by means of a 
26-gauge needle. In 24 of the 300 patients, intracavernous injection of 
this mixture led to prolonged erections (persisting 6 h), associated with 
painful tension of the penile shaft in 3 cases (Table 1). Although only 
3.7 mg papaverine and 0.12 mg phentolamine were injected the follow- 
ing day, another prolonged erection occurred in 2 of the 24 patients. 
The first 4 cases of prolonged erection were treated by aspiration 
and lateral puncture of the proximal third of both corpora cavernosa us- 
ing a 19-gauge needle. The other 20 patients were administered 
metaraminiol intracavernosally, the first 7 being injected with 2.5 mg us- 
ing a 26-gauge cannula, the remaining with 2.0 mg in the right proximal 
corpus cavernosum. Previous aspiration of blood was omitted. 
Group 3 (prolonged erection during auto-injection therapy) 
During auto-injection therapy at home, only 3 patients reported the oc- 
currence of 1 prolonged erection each, persisting for 6-12~-h 
(mean = 8 h). A total of 4813 auto-injections were documented. The 
prolonged erections occurred espite individual dosing for induction of 
an erection of 30-90 min duration. In each of the 3 cases, the patient 
had self-injected a second dose after thinking the first injection was un- 
successful. 
Group 4 (interruption f erection due to injection of vasoactive 
substances) 
To unveil possible circulatory side effects of the intracavernous injection 
of metaraminiol, 20 patients with erectile dysfunction responding to the 
intracaverous injection of papaverine and phentolamine with a full erec- 
tion were injected 2mg metaraminol intracavernosally following 
diagnostic injection (average dosage 13.5 mg papaverine and 0.45 mg 
phentolamine). Metaraminol was injected after half of the expected in- 
dividual duration of erection (72 min). Each of these patients consented 
to this study. 
Group 5 (accidental prolonged erection in potent men) 
Two potent men (24 and 41 years) self-administered an intracavernosal 
injection of a vasoactive mixture ,,in order to achieve greater satisfac- 
tion for the sex partner". Both men injected a solution of papaverine 
hydrochloride (7.5 mg) and phentolamine m sylate (0.25 mg) that had 
been supplied by other hospitals. The injections produced erections per- 
sisting for 6 and 18.5 h respectively. The second patient experienced 
painful tension of the penile shaft after 12 h of erection. 
A third, 60-year-old, patient, capable of having normal coitus with 
full erections every 14 days, was injected papaverine hydrochloride 
(30 mg) by his urologist. As there was no effect within 10 min after ad- 
ministration, another 30 mg were injected and the patient was sent 
home with a complete rection. After 24 h he returned with a painful 
prolonged erection. At the office, intracavernous injection of 4 mg 
mataraminol had no effect. After 2 more hours, he was admitted to our 
hospital with a palpable, complete, painful erection. 
Group 6 (erection during TUR) 
A 71-year-old patient with a history of unimpaired sexual potency and 
coronary heart disease was to undergo transurethral resection for 
benign prostatic hyperplasia (BPH). Introduction of the resectoscope 
caused an erection with palpable full rigidity persisting for 15 min, 
which made transurethral resection impossible. In order to interrupt the 
erection, metaraminol (2 mg) was injected in the right proximal corpus 
cavernosum. 
Results 
Group 1 (control group) 
All 10 potent man exhibited complete flaccidity 
9 -22  min (mean = 13.t min) after intracavernous injec- 
tion of metaraminol (2 mg) in the right proximal corpus 
cavernosum. The ability to have spontaneous erections on 
the next day was not impaired. 
Group 2 (prolonged erection during diagnosis) 
In the first 4 prolonged erections aspiration of 
210-  400 ml (mean = 3 ! 5 ml) of unclotted blood produc- 
ed constant flaccidity in all cases. Residual spontaneous 
activity and the response to intracavernosal injection of 
vasoactive substances on the third day after puncture 
were unchanged as compared with the previous tate, i.e., 
before the prolonged erection. 
The following 22 prolonged erections ubsided after 
intracavernous metaraminol (2.5 or 2.0 mg). Complete 
flaccidity was attained after 7 -20min  (mean = 
14.4 min); the difference between the two doses was not 
statistically significant. The response to intracavernous 
injection of vasoacitve drugs on the next day was not im- 
paired. 
Group 3 (prolonged erection during auto-injection 
therapy) 
Intracavernosal injection of metaraminol (2.5 mg) in the 
rigth proximal corpus cavernosum did not reduce rigidity 
in any of the three patients. The erection did not subside 
Fig. 1. Dynamic cavernosography 48 hafter treatment of a 26-h pro- 
longed erection by puncture and aspiration. Maintainance- 
flow = 148 ml/min 
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Fig. 2. Doppler sonography before, and 
5 and 20 rain after erection i duced by 
vasoactive drugs 
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Fig. 3 a, b. Intracavernous blood gas analysis performed in 12 patients 
with pharmacologically induced full erections. The analysis was done in 
3 patients after 2 h, in 3 patients after 4 h, in 3 patients after 6 h, in 2 
patients after 12 h and in 1 patient after 26 h. a With duration of the 
full erection, pO 2 decreases and pCO 2 increases ignificantly, b Simul- 
taneous to the changes in Fig. 3 a, pH decreases and the negative base 
excess increases dramatically 
until, 10 min later, 1 mg of metaraminol was additionally 
injected into the proximal left corpus cavernosum. Com- 
plete flaccidity was attained ca. 15 min after the second 
injection. 
Group 4 (interruption f erection due to injection of 
vasoactive substances) 
Intracavernosal injection of metaraminol (2 mg) in the 
right proximal corpus cavernosum caused complete flac- 
cidity within 3.5-12 min (mean = 7.7 min) in all 20 pa- 
tients. 
Group 5 (accidental prolonged erection in potent men) 
In the first two subjects, the erection subsided after 
metaraminol (2 mg) had been injected in the right prox- 
imal corpus cavernosum; flaccidity was attained after 
about l0 min. 
The third subject, who had received the papaverine 
dose twice had been administered an injection of 
metaraminol (4mg) in the right corpus cavernosum by his 
urologist. As there was no apparent decrease in rigidity 
within 1 h, he was referred to our hospital. 
The blood gas analysis performed after 26 h of com- 
plete erection yielded a pH of 6.87, PO2 of 19 mmHg, 
pCO2 of 73 mmHg and a base excess of -25.  As the in- 
jection of metaraminol (3 mg) in the left corpus caver- 
nosum did not produce any decrease in rigidity within 
15 min, both corpora cavernosa were punctured with a 
19-gauge cannula using an antibiotic for prophylaxis 
(Ceftacidin 2 g i.v.). Aspiration led to immediate detu- 
mescence; 520 ml of dark, unclotted blood was with- 
drawn (the blood clotted in the kidney dish within 7 min). 
Thereafter, the following blood gas values were obtained: 
pH 7.44, PO2 77 mmHg, pCO2 35 mmHg, base excess 
+ 1.0. Before the cannulas were removed, metaraminol 
(2 mg) was injected into the right corpus cavernosum. No 
spontaneous erection occurred within the next 24h. 
Cavernosography showed pathologic venous outflow 48 h 
following puncture without any evidence of thrombotic 
obliteration of the venous drains (Fig. 1). 
After 3 months, the patient reported complete loss of 
spontaneous full erectability. He did not respond to max- 
imal doses (3 ml) of a standardized vasoactive solution 
(papaverine hydrochloride 15 mg/ml and phentolamine 
mesylate 0.5 mg/ml) with full erection. 
Group 6 (erection during TUR) 
Intracavernosal injection of metaraminol (2 mg) led to 
complete flaccidity within 57 min. The ECG 3 min after 
injection showed atrial extrasystoles for about 140sec, 
which did not call for treatment and ceased without 
therapy. During this time, the systolic blood pressure in- 
creased by 15 mmHg. 
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Discussion Conclusion 
Under  the precondit ion o f  adequate neurogenic stimula- 
t ion, d i latat ion of  the penile arteries, part icular ly of  the 
aa. profundae penis, relaxation of  the cavernosal 
sinusoids and constr ict ion or compression of  the penile 
veins results in an erection with full r igidity [6]. The ap- 
parent hemodynamic  changes caused by neurogenic 
st imulat ion correspond to those seen after intracavernous 
inject ion of  vasoactive substances [8]. 
Our  Doppler  tests per formed on the a. profunda 
penis show that the intracavernous injection of  vasoactive 
substances causes a strong increase in b lood flow within 
30sec. This flow increase reaches a max imum after 
4 -6min ,  but is no longer detectable by Doppler  
u l t rasonogaphy 20 min after a complete rection has been 
achieved (Fig. 2). This, together with b lood gas analysis, 
which deteriorates with the durat ion of  the erection (Fig. 
3), gives the characterist ic picture of  a low-flow or even 
no-f low pr iap ism [7]. 
This condit ion is l ikely to have its origin in a maximal  
relaxat ion o f  the intracavernosal  smooth muscles. This 
maximal  relaxation can be interrupted by intracavernosal 
inject ion of  a lpha-sympathomimet ics ,  as our results have 
been able to demonstrate.  When,  however, pronounced 
ischemic changes associated with a low tissue pH are pre- 
sent in the corpus cavernosum as a result o f  a persisting 
erection, it seems that the low pH blocks the effect of  the 
a lpha-receptor  st imulant.  This condit ion calls for an in- 
vasive procedure with puncture of  the corpora cavernosa 
and aspirat ion of  ischemic blood. The introduct ion of  a 
g landulocavernosal  shunt was not necessary in our pa- 
tients. 
The absence of  subjective and objective adverse car- 
diovascular effects to the intracavernous injection of  
metaraminol  (2.0 and 2.5 mg) is due on the one hand to 
the low doses used and, on the other, to preselection of  
the populat ion  as patients with severe cardiovascular dis- 
ease were excluded. Possible untoward effects affecting 
the heart, which was noted in the one patients of  group 
6, just i fy rigid preselection criteria, all the more so, since 
severe paroxysmal  hypertension and allergic reactions 
fol lowing intravenous doses o f  metaraminol  have been 
descr ibed [1]. 
The pro longed erections during diagnosis and therapy 
did not cause any of  the patients to reject or dicontinue 
auto- in ject ion therapy. The three cases of  prolonged erec- 
t ions under home treatment occurred during the first 6 
months  in which this kind of  therapy was used at our hos- 
pital. Since, on the basis o f  this experience, we now warn 
our patients not to apply  more than one auto- inject ion 
per day, even if the injection appears to be unsuccessful, 
we have received no further reports on persisting erec- 
t ions during home treatment within the last 17 months. 
Pro longed erections resulting from intracavernous injec- 
t ion of  vasoactive substances should be stopped after 3 h 
and in no case be allowed to persist for more than 6 h, as 
they involve the risk of  ischemic damage to the cavernous 
tissue with resulting irreversible erectile impotence. A 
simple method is the intracavernous injection of  2 mg 
metaraminol .  When repeated injection of  I mg meta- 
raminol  fails to produce f laccidity in the case of  per- 
sisting rigidity, puncture and aspirat ion of  the corpora 
cavernosa re required. 
The use of  vasoactive substances for diagnostic and 
therapeutic purposes in patients with erectile dysfunction 
as well as the administrat ion of  antagonist ic a lpha-sym- 
pathomimetics require careful preselection of  the popula-  
tion, cooperat ion of  the individual patient, and the full 
responsibi l i ty of  the treating physician, who must be 
aware that he is working with highly potent drugs. 
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